Skip to main content

NUEVOS MATERIALES Y SONDAS PARA EL RECONOCIMIENTO, LIBERACION DE FARMACOS, NANOMOTORES Y COMUNICACION

PRE2022-103714

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprogram Subprograma Estatal de Formación
Call Contratos Predoctorales
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSITAT POLITÈCNICA DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Glucose-Fueled Gated Nanomotors: Enhancing In Vivo Anticancer Efficacy via Deep Drug Penetration into Tumors

  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Hicke-García, Francisco Javier|||0000-0002-8419-0467
  • Esteve-Moreno, Juan José|||0000-0002-1259-7663
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Lucena-Sánchez, Elena
  • Pradana-López, Sandra
  • Sanz-Álvarez, Víctor
  • Garrido-Cano, Iris
  • Torres-Ruiz, Sandra
  • Cejalvo, Juan Miguel
  • Diez-Sánchez, Paula
[EN] Bioinspired nano/micromotors with drug delivery capabilities are emerging tools with the promising potential to treat numerous diseases. However, some major challenges must be overcome before reaching real biomedical applications. Above all, it is necessary to design engines that employ biocompatible and bioavailable fuels to induce efficient propulsion in biological environments. In addition, ideal nanomotors should also be capable of delivering the cargo on-command using selected stimuli. To tackle these challenges, we herein present the design and evaluation (both in vitro and in vivo) of a glucose-driven gated Janus nanomotor that performs on-demand anticancer drug delivery to treat solid tumors. The motor's nanoarchitectonics is based on the anisotropic conjunction of catalytic platinum nanodendrites (PtNds) and a mesoporous silica nanoparticle (acting as a nanocontainer for anticancer drug doxorubicin) capped with enzyme glucose oxidase (GOx). Autonomous nanomotor movement is achieved thanks to two catalytic components, GOx and PtNds, in a hybrid cascade reaction: GOx transforms glucose to give H2O2 that is subsequently catalyzed by PtNds into H2O and O2. Besides, gatekeeper moieties (GOx) respond to the presence of intracellular proteases, which induces doxorubicin delivery. Biological experiments with the nanomotor are carried out in cancer cell cultures, three-dimensional (3D) tumor models (spheroids), in vivo and in patient-derived organoids (PDOs). A strong anticancer effect is found and attributed to the synergistic combination glucose-induced propulsion, controlled drug delivery, elimination of glucose (by GOx), ROS production (H2O2 generation by GOx) and hypoxia reduction (O2 generated by PtNds). Taken together, this study advances the engineering of endogenously fueled nanomotors for in vivo operation and provides insights into the application of active particles in cancer therapy toward clinical application., The authors acknowledge the financial support from Project PROMETEO 2018/024 from the Generalitat Valenciana, Project RTI2018-100910-B-C41 and PID2021-126304OB-C41 funded by MCIN/AEI and FEDER, Project MFA/2022/049 from Advanced Materials program funding by European Union NextGenerationEU (PRTR-C17.I1) and the Generalitat Valenciana and the European Research Council (ERC) via Advanced Grant (101052997, EDISON). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Research Council. Neither the European Union nor the granting authority can be held responsible for them. A.E. thanks the Generalitat Valenciana for her PhD grant (ACIF/2018/110). F.J.H. thanks MIU for his FPU grant (FPU20/06021). E.L.-S. is also grateful for her FPU fellowship funded by MINECO (FPU18/06539). P.D. thanks the Instituto de Salud Carlos III and the European Social Fund for financial support "Sara Borrell" (CD20/00120) and Scientific Foundation of the Spanish Association Against Cancer (AECC) for her postdoctoral grant (INVES246470DIEZ). S.P.-L. thanks Investigo program of the Spanish Government funded by NextGenerationEU from the European Union. V.S.-A. thanks MIU for his FPI grant (PRE2022-103714), J.J.E.-M. thanks the AECC Scientific Foundation for his PhD grant (PRDVA21651ESTE). I.G.-C. was funded by Margarita Salas postdoctoral grant (European Union-Next generation EU). J.M.C. was funded by Sociedad Espanola de Oncologia Medica (Juan Rodes-SEOM). The authors are especially thankful to the associations Amunt Contra el Cancer, La Venuseta, Corazon Solidario Contra el Cancer, Mou-te Per Elles, and Asociacion Las Triples. Scheme A and Figures A-i,B-i, A-i, A, A, and A were created with BioRender.com https://BioRender.com/xs7c89a